With the opening of its state-of-the-art facility in Rockville in 2017, GSK has been strengthening its manufacturing presence in the US. As a result, the site’s portfolio of programs and bulk production has been growing steadily, with
Biotech, Medtech, and pharma companies of all shapes, sizes, and focus areas are struggling to fill vacancies during a growth boom created by the pandemic and advancements in biomanufacturing, cell and gene therapy, and other bleeding-edge sectors. This ongoing boom has created an uber-competitive talent acquisition and retention environment that’s pushing hiring managers, talent leaders, and c-suite executives to evolve and adopt new talent hiring and retention strategies that give them a competitive hiring edge.
GSK is hiring for a large number of full-time jobs to support an expanding portfolio of programs and the growth of their bulk production of several critical drugs manufactured at the site.
Maryland’s reputation as the destination state for biotech jobs and life science research continues to climb as new startups emerge across its biohealth cluster regions.
Maryland’s leading vaccine manufacturer, Emergent Biosolutions (Emergent), is a critical cog in the vaccine manufacturing and distribution engine as it has multiple COVID-19 vaccine manufacturing partnerships, including partnerships with J&J and AstraZeneca, among others. Emergent also partners with the Biomedical Advanced Research and Development Authority (BARDA), which provided approximately $628.3M in funding to the company as part of Operation Warp Speed.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
Growing your business means aligning your executive team with your objectives. How do you know when new voices are needed? How do you recruit and retain the right voices?
Lonza Pharma and Biotech (Lonza) is one of the world’s leading contract development and manufacturing organizations with 37 sites across the U.S., Europe, Asia, and the Middle East.
The pandemic changed everything. We live differently, behave differently, and have come to appreciate the little things we might have taken for granted before COVID-19 took hold in the BioHealth Capital Region (BHCR).
In an incredibly short time, Gaithersburg, Maryland’s Novavax has advanced its SARS-CoV-2 vaccine candidate into Phase III trials and received FDA fast track designation, putting its vaccine very close to potential FDA approval. There has been a herculean effort underway by Novavax and other companies to deliver desperately needed pandemic protection to people across the globe.
